PharmaResearch Co., Ltd. (KOSDAQ:214450)
340,500
+13,500 (4.13%)
Jul 21, 2026, 2:40 PM KST
PharmaResearch Revenue
PharmaResearch had revenue of 146.10B KRW in the quarter ending March 31, 2026, with 24.97% growth. This brings the company's revenue in the last twelve months to 565.48B, up 44.14% year-over-year. In the year 2025, PharmaResearch had annual revenue of 536.29B with 53.18% growth.
Revenue (ttm)
565.48B
Revenue Growth
+44.14%
P/S Ratio
6.01
Revenue / Employee
1.04B
Employees
542
Market Cap
3.40T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 536.29B | 186.17B | 53.18% |
| Dec 31, 2024 | 350.12B | 89.10B | 34.14% |
| Dec 31, 2023 | 261.01B | 66.25B | 34.02% |
| Dec 31, 2022 | 194.76B | 40.68B | 26.40% |
| Dec 31, 2021 | 154.08B | 45.34B | 41.69% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.81T |
| Celltrion | 4.47T |
| Samsung Epis Holdings | 1.51T |
| SK bioscience | 665.42B |
| CLASSYS | 346.88B |
| Sam Chun Dang Pharm. | 246.05B |
| ALTEOGEN | 203.76B |
| LigaChem Biosciences | 125.87B |